Physician profile
Mary E Mcallister
NPI 1790723989
$613.88
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.07 · 2021: $65.16 · 2022: $236 · 2023: $158 · 2024: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $292.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $106.36 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.07 | 2022-2024 | Entyvio, Eohilia |
| Intercept Pharmaceuticals, INC. | $86.51 | 2022-2024 | Ocaliva |
| Qol Medical, LLC | $74.44 | 2021-2022 | |
| Braintree Laboratories, INC. | $55.58 | 2022-2024 | Sutab, Suflave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.66 | 2022-2023 | Xifaxan |
| Ardelyx, INC. | $20.00 | 2023 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $19.80 | 2022 | |
| Fresenius Kabi USA, LLC | $18.16 | 2023 | Idacio |
| Alnylam Pharmaceuticals INC. | $17.91 | 2022 | |
| Lilly USA, LLC | $17.58 | 2024 | Omvoh |
| Merck Sharp & Dohme LLC | $15.54 | 2023 | Dificid |
| Redhill Biopharma INC. | $14.02 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $13.67 | 2024 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $13.58 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Mcallister listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.